

July 9, 2013



# Actinium Pharmaceuticals Clinical Results Featured at a United Nations Forum

**Actinium's lead drug candidate and technology platforms were discussed in a presentation at the IAEA technical meeting in Vienna, Austria**

NEW YORK, July 9, 2013 /PRNewswire/ -- Actinium Pharmaceuticals Inc. (OTCQB: ATNM), a biopharmaceutical company that develops innovative targeted payload immunotherapeutics for treatment of advanced cancers, announced that the Actinium Pharmaceuticals' clinical programs and platform technology were presented in Vienna, Austria, at a technical meeting at the International Atomic Energy Agency (IAEA). The presentation was delivered by Dr. David Scheinberg, Interim Director of the Sloan-Kettering Institute, research division of the Memorial Sloan-Kettering Cancer Center.

"There is increasing interest in the uses of alpha particle therapy around the world," said Dr. Scheinberg. "We now see scientists, clinicians, isotope manufacturers, government agencies and commercial companies collaborating to enable therapeutic advances of these agents against cancer."

Dr. Scheinberg's presentation focused on Actinium Pharmaceuticals' drug candidates Actimab-A and Bismab for acute myeloid leukemia as well as applications of alpha immunotherapy in treatment of solid cancers. The IAEA meeting at the United Nations headquarters in Vienna, Austria, was a closed workshop entitled "Alpha Emitting Radionuclides and Radiopharmaceuticals for Therapy".

## **About Actimab - A**

Actimab-A is a drug candidate construct made using Actinium Pharmaceuticals' proprietary patented technology for arming monoclonal antibodies with alpha emitters actinium-225 and bismuth-213. Antibodies are used as high precision delivery systems that bring powerful alpha emitters into or immediately next to targeted cancer cells. Actimab-A consists of the Lintuzumab monoclonal antibody and actinium-225.

Actinium-225 decays by giving off high-energy alpha particles, which kill cancer cells. When actinium decays, it produces a series of daughter atoms, each of which gives off its own alpha particle, increasing the chances that the cancer cell will be destroyed. The technology was first developed by Dr. David Scheinberg at Memorial Sloan-Kettering Cancer Center.

## **About Actinium Pharmaceuticals, Inc.**

Actinium Pharmaceuticals, Inc. is a New York, NY based biopharmaceutical company that develops innovative alpha particle immunotherapeutics based on its proprietary platform for the therapeutic utilization of alpha particle emitting actinium-225 and bismuth-213 radiopharmaceuticals in association with monoclonal antibodies.

**For more information:**

Visit our web site [www.actiniumpharmaceuticals.com](http://www.actiniumpharmaceuticals.com) or

**Contact:**

Segio Traversa, CEO

Actinium Pharmaceuticals Inc.

E-mail: [straversa@actiniumpharmaceuticals.com](mailto:straversa@actiniumpharmaceuticals.com)

**Media:**

Dennis S. Dobson Jr.

Tel: (203) 258-0159

E-mail: [dsdobson@optonline.com](mailto:dsdobson@optonline.com)

[www.dobsonmediagroup.com](http://www.dobsonmediagroup.com)

**Forward-Looking Statement for Actinium Pharmaceuticals, Inc.**

This news release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential, or financial performance. No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Actinium Pharmaceuticals undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.

SOURCE Actinium Pharmaceuticals